score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High	Clinical trial			Somatic Variant	ATM	Splice Site	p.2124+1G>T						Investigate Actionability - High	BAY 1895344	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007																ATM p.2124+1G>T (Splice Site)		A004		
Investigate Actionability - High	Clinical evidence			Copy Number	EGFR	Amplification							Investigate Actionability - High	Gefitinib	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.	https://doi.org/10.1200/JCO.2005.01.0793																EGFR Amplification		A004		
Investigate Actionability - High	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Y229*						Investigate Actionability - High	Durvalumab	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z							Investigate Actionability - Low	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Y229* (Nonsense)		A004		
Investigate Actionability - High	Preclinical		Preclinical	Copy Number	AURKA	Amplification							Investigate Actionability - High	Danusertib	Targeted therapy	Neuroendocrine prostate cancer (NEPC) cell lines shows enhanced sensitivity to pan-Aurora kinase inhibitor therapy, specifically to PHA-739358 (Danusertib).	Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1(6):487-95.	https://doi.org/10.1158/2159-8290.CD-11-0130							Investigate Actionability - High	0	Downmodulation of TPX2 and AURKA in the presence of 20q copy gain was shown to tumor growth	"Sillars-Hardebol, Anke H., et al. ""TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression."" Gut 61.11 (2012): 1568-1575."	https://doi.org/10.1136/gutjnl-2011-301153					AURKA Amplification		A004		
Investigate Actionability - High	Preclinical			Copy Number	CDKN2B	Deletion							Investigate Actionability - High	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214																CDKN2B Deletion		A004		
Investigate Actionability - High	Preclinical			Copy Number	CDKN2A	Deletion							Investigate Actionability - High	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214																CDKN2A Deletion		A004		
Investigate Actionability - High	Preclinical			Copy Number	FGFR1	Amplification							Investigate Actionability - High	Infigratinib	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210																FGFR1 Amplification		A004		
Investigate Actionability - High	Inferential		Clinical evidence	Copy Number	CCND1	Amplification							Investigate Actionability - High	Palbociclib	Targeted therapy	CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744							Investigate Actionability - High	0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506					CCND1 Amplification		A004		
Investigate Actionability - High			Clinical evidence	Copy Number	MYC	Amplification																			Investigate Actionability - High	0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y					MYC Amplification		A004		
